LifeVantage Swings to $196K Q1 Loss as Revenue Falls 22% to $37.1M
LFVN sits 28% above its 52-week low of $3.9.
Summary
LifeVantage's fiscal Q1 revenue fell 22% to $37.1M and the company swung to a $196K net loss as gross margin compressed on inventory write-downs and active accounts fell 19%.
Key Events · Earnings and Guidance · LFVN
-
Q1 Revenue Falls 22% to $37.1M
Net revenue was $37.1M versus $47.6M a year earlier, driven by a $4.4M drop in MindBody GLP-1 System sales, a $4.1M decline in Protandim and $2.3M lower TrueScience, partly offset by $1.7M from the acquired LoveBiome line.
-
Swing to $196K Net Loss
Net loss was $196K, or $(0.02) per diluted share, versus net income of $2.155M, or $0.17, a year ago; operating result was a $136K loss against $2.268M of income.
-
Gross Margin Drops to 75.4%
Cost of sales rose as a share of revenue to 24.6% from 20.5%, mainly on $1.3M of inventory obsolescence charges, of which $1.0M related to the MindBody GLP-1 System, plus higher shipping and warehouse costs.
-
Active Accounts Down 19%
Total Active Accounts fell to 98,000 from 121,000 and Active Customers to 58,000 from 73,000; Americas accounts dropped 20.9% and Asia/Pacific & Europe 13.3%.
Analysis · LFVN · Life Sciences
The top line was already out this morning, but the 10-Q shows the damage reached the bottom line: revenue fell 22% to $37.1M and the company posted a $196K net loss versus $2.155M of profit a year ago. Gross margin dropped to 75.4% from 79.5%, with $1.3M of inventory obsolescence charges (including $1.0M on the MindBody GLP-1 System) doing most of the damage. Demand is the underlying problem: Active Accounts are down 19.0% to 98,000 and Active Customers down 20.5% to 58,000, so the erosion is in the sales force, not just one product. Cash slipped to $13.7M from $14.9M, but operating cash flow turned positive at $0.5M and the $5.0M revolver is undrawn, so there is no near-term liquidity crisis. The board also moved the fiscal year-end to December 31, which will make the next reported period a six-month transition stub.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFVN was trading at $5.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.6M. The 52-week trading range was $3.90 to $11.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.